Primary malignant neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
Overall, our results suggest that DETD-35 may be useful as a therapeutic or adjuvant agent against BRAF(V600E) mutant and acquired vemurafenib resistance melanoma.Mol Cancer Ther; 15(6); 1163-76.©2016 AACR.
|
27048951 |
2016 |
Primary malignant neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
We previously repositioned the drug as the inhibitor of B-Raf V600E, but its anti-tumor effect in human cancer has never been reported.
|
30583070 |
2019 |
Primary malignant neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
Using patient-derived (V600E)BRAF melanoma cells, we found that low-glutamine-induced histone hypermethylation resulted in cancer cell dedifferentiation and resistance to BRAF inhibitor treatment, which was largely mediated by methylation on H3K27, as knockdown of the H3K27-specific demethylase KDM6B and the methyltransferase EZH2 respectively reproduced and attenuated the low-glutamine effects in vitro and in vivo.
|
27617932 |
2016 |
Primary malignant neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
Recently, increasing evidences indicate that BRAF((V600E)) mutation is a specific molecular feature and driver of the serrated pathway, and proximal serrated polyps with BRAF((V600E)) mutation have a high risk of progression to malignancy.
|
25550768 |
2014 |
Primary malignant neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
The increased incidence of cancer in FDRs of index CRC patients with the p.V600E BRAF mutation may be explained by a genetic predisposition to develop cancer through the serrated pathway of colorectal carcinogenesis.
|
20570909 |
2010 |
Primary malignant neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
Recent developments in v-raf murine sarcoma viral oncogene homolog B1 (BRAF)(V600E)-specific small molecule inhibitors and their clinical approval for other cancer types could turn BRAF(V600E) into a promising molecular predictor of outcome in pilocytic astrocytomas, given a treatment with a mutation-specific BRAF inhibitor is applied.
|
23160425 |
2012 |
Primary malignant neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
One (1.6%) cancer tissue sample showed a point mutation in the BRAF gene (GTG --> GAG; V599E).
|
15616773 |
2004 |
Primary malignant neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
To evaluate the association of BRAF(V600E) mutation with US features of thyroid nodules in predicting the malignancy of thyroid nodules in Korean patients.
|
21707687 |
2011 |
Primary malignant neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
None of the 504 benign, 45 (31.9%) of the 141 ACUS, 46 (85.2%) of the 54 suspicious for malignancy, 129 (92.1%) of the 140 malignant, and one (10%) of the 10 suspicious for follicular neoplasm cases showed BRAF(V600E) mutation.
|
21239517 |
2011 |
Primary malignant neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
These data demonstrate that clonal BRAF(V600E) is a rare occurrence in PTC, although frequently this cancer consists of a mixture of tumor cells with wild-type and mutant BRAF.
|
22170714 |
2012 |
Primary malignant neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
The presence of the noninheritable V600E BRAF mutation in this family supports Knudson's "double-hit" hypothesis for cancer development and suggests the involvement of more than 1 gene in the clinical expression of FNMTC.
|
29895015 |
2018 |
Primary malignant neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
Detection of BRAF(V600E) mutation had limited value in diagnoses of malignancy in follicular neoplasms but can ascertain malignancy in subset of suspicious for malignancy FNABs.
|
21948220 |
2011 |
Primary malignant neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
This study sought to determine if cytologic markers of malignancy are associated with the BRAF(V600E) mutation and if preoperative BRAF(V600E) testing would alter the initial management of patients with indeterminate nodules.
|
23280049 |
2013 |
Primary malignant neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
The BRAF gene has been identified as an oncogene in human cancer and the V600E mutation has been shown to be associated with clinico pathological features of primary invasive melanomas.
|
21262211 |
2011 |
Primary malignant neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
For the 37 cases cytologists favored to be cPTC, 31 (84%) had a molecular result that supported malignancy (28 BRAF V600E mutations, 2 NTRK1 fusions, 1 AGK-BRAF fusion).
|
29396809 |
2018 |
Primary malignant neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
Interesting, Prof. Peng Hou and colleagues, at the First Affiliated Hospital of Xi'an Jiaotong University in China, identified unknown epigenetic mechanisms and their involvement in the tumorigenesis of B-RAF(V600E)-driven cancer.
|
28638488 |
2017 |
Primary malignant neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
Braf(V600E)-driven tumors require autophagy and likely autophagy-provided substrates to maintain mitochondrial metabolism and to promote tumor growth, suggesting that autophagy ablation may improve cancer therapy.
|
24860158 |
2014 |
Primary malignant neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
Furthermore, when we introduce the equivalent of the most common cancer mutation in B-RAF (V600E) into C-RAF, it only has a weak effect on kinase activity and does not convert C-RAF into an oncogene.
|
16266992 |
2005 |
Primary malignant neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
The frequency of malignancy and the BRAF(V600E) mutation were compared between suspicious and probably benign nodules on US and between groups 1 and 2.
|
20945104 |
2011 |
Primary malignant neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
The AUS-NA subcategory was associated with the highest risk of malignancy and the greatest frequency of BRAF V600E (substitution of valine to glutamic acid at position 600) mutation.
|
24619974 |
2014 |
Primary malignant neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF(V600E)-mutated DNA was quantified in plasma samples and in cancer sections by quantitative real-time polymerase chain reaction (qPCR).
|
24858900 |
2014 |
Primary malignant neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
The BRAF (V600E) mutation is found in several human cancer, causing an increase of cell proliferation due to a modification of the ERK/MAPK-signal cascade.
|
31762942 |
2019 |
Primary malignant neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
The usefulness of immunohistochemistry (IHC) as a new approach for the detection of BRAF V600E in cancer patients has been recently reported.
|
23927882 |
2013 |
Primary malignant neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF V600E Gene Mutation Is Associated With Bilateral Malignancy of Papillary Thyroid Cancer.
|
30219154 |
2018 |
Primary malignant neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
These findings indicate that adenomas might be less important in the cancer development in the group of families with BRAF-V600E mutations and indirectly support a previous hypothesis that tumors might develop through the hyperplastic polyp-serrated adenoma pathway.
|
17119056 |
2006 |